Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.
Federal funding to develop and clinically test non-opioid pain drugs—a high-priority unmet medical need with regulatory tailwinds.
Report stale or inaccurate summary
What this is
This is an NIH HEAL Initiative grant supporting early-to-advanced development of novel non-opioid analgesics for pain treatment. Applicants can propose small molecules, biologics, or combination approaches, with the UG3/UH3 structure allowing optional transition to clinical trials. This targets the urgent public health need to expand pain management options beyond addictive opioids. The mechanism suits both basic research and translational teams ready to move toward clinical validation.
Who can apply
Eligibility not explicitly specified in the source material, but UG3/UH3 mechanisms typically support domestic institutions including universities, non-profits, small businesses, and established companies with relevant research capacity. Contact NIH program officer for specific organization-type and prior-funding requirements.
Topics: non-addictive pain therapeutics · HEAL initiative · small molecule drug development · biologic therapeutics · opioid alternative · clinical trial funding · NIH UG3/UH3
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.